Gardnerella Vaginalis DNA: What a Positive Test Means

A positive Gardnerella vaginalis DNA test means the bacterium’s genetic material was detected in your sample, but it does not, on its own, mean you have bacterial vaginosis or any infection at all. Gardnerella vaginalis lives in the vaginal tract of a large majority of women regardless of whether they have symptoms. What matters far more than a simple “detected/not detected” result is the quantity of the organism, what other bacteria are present alongside it, and whether you have symptoms. The gap between “positive test” and “diagnosis” is wide enough that understanding it can save you unnecessary worry and treatment.

Why Gardnerella Vaginalis Shows Up in Healthy Women

Gardnerella vaginalis is part of the normal vaginal microbiome for most women. In one study examining women who did not have bacterial vaginosis (BV), Gardnerella vaginalis was found in 87% of them.¹ That number alone should reshape how you think about a positive DNA test. The organism is not some rare invader that appears only when something has gone wrong. It is a routine resident that, under certain conditions, can overgrow and participate in disease.

The difference between health and disease in this case is largely about proportions. In a healthy vaginal environment, Lactobacillus species dominate, producing lactic acid that keeps the pH low and limits the growth of other organisms. Laboratory research has confirmed that Lactobacillus crispatus, for example, produces lactic acid that directly inhibits growth of Gardnerella vaginalis.² Some strains of Lactobacillus go further, releasing antibiotic-like compounds that can kill Gardnerella and protect cervical cells from its toxin-producing effects.³ When that protective Lactobacillus population shrinks, Gardnerella and other anaerobic bacteria can expand unchecked, leading to BV.

A Positive DNA Result Is Not the Same as a BV Diagnosis

DNA-based tests, usually performed by polymerase chain reaction (PCR), are extremely sensitive. They can pick up even tiny amounts of Gardnerella genetic material. That sensitivity is a double-edged sword. A PCR test for Gardnerella vaginalis will come back positive for the vast majority of women tested, whether or not they have BV. What clinicians and researchers have found is that the bacterial load, not mere presence, is what separates BV from normal flora.

One study found that all women whose vaginal flora scored as BV on the standard microscopy grading system (Nugent score) had Gardnerella loads of at least 10 million copies per milliliter. Meanwhile, the negative predictive value at that threshold was 100%, meaning if your load was below that cutoff, you almost certainly did not have BV.⁴ A separate study pushed the diagnostic threshold even higher, finding that Gardnerella loads at or above one billion copies per milliliter, combined with elevated levels of a second organism called Atopobium vaginae, yielded the highest predictive value for BV, with about 95% sensitivity and 99% specificity.⁵

In other words, a positive-or-negative result tells you very little. A quantitative result, showing how much Gardnerella DNA is present, tells you much more. And even a quantitative result is most informative when paired with measurements of other organisms. If your test report only says “detected,” it is essentially telling you that you have a vaginal microbiome, which is not news.

How Multi-Organism Panels Improve Accuracy

Modern PCR-based diagnostics for BV have moved beyond looking at Gardnerella alone. The most accurate approaches quantify several bacterial species at once. A validated assay targeting Gardnerella vaginalis, Atopobium vaginae, and two species of Megasphaera achieved 92% sensitivity and 95% specificity for BV, with a positive predictive value of 94%.⁶ Another multiplex PCR assay found that among women with confirmed BV, Gardnerella was detected in 96%, Atopobium vaginae in 87%, and Megasphaera in 60%. Among women with normal flora, those numbers dropped to 27%, 6%, and 2% respectively.⁷

Notice the pattern: Gardnerella alone still showed up in over a quarter of healthy women on that PCR panel, but the companion organisms were far more discriminating. A test that combines Gardnerella with Atopobium vaginae and Lactobacillus counts improved sensitivity and specificity to 83% and 78% compared with traditional microscopy scoring.⁸ The lesson for you as a patient: if your report shows a panel of organisms with their respective loads, the overall pattern is far more meaningful than any single line item.

Not All Gardnerella Are Created Equal

One of the more surprising developments in recent years is the discovery that what labs call “Gardnerella vaginalis” is actually a group of genetically distinct species. Whole genome analysis of 81 Gardnerella genomes revealed at least 13 separate genomic species, of which four have been formally named as new species beyond the original Gardnerella vaginalis.⁹ These species differ in their potential to cause disease.¹⁰

This matters because a standard DNA test for “Gardnerella vaginalis” may not distinguish between a relatively harmless species that commonly lives in healthy women and one with stronger disease-causing potential. Some Gardnerella species produce an enzyme called sialidase, which breaks down the protective mucus lining of the vagina, and a toxin called vaginolysin that damages epithelial cells. In one collection of Gardnerella isolates from women with BV, sialidase genes were present in all 24 samples and the vaginolysin gene in about 79%.¹¹ But the distribution of these virulence traits varies across species, and most commercial DNA tests don’t yet report which Gardnerella species you carry. Until they do, a positive result lumps the more dangerous strains together with the benign ones.

The Biofilm Problem and Why BV Keeps Coming Back

One of the most frustrating aspects of BV for people who experience it is the high rate of recurrence. The explanation lies in biofilms: structured communities of bacteria that adhere to the vaginal wall and are much harder for antibiotics to penetrate than free-floating bacteria. Research has shown that even after a full course of oral metronidazole, a dense biofilm primarily composed of Gardnerella vaginalis and Atopobium vaginae persists on the vaginal lining and resurges once treatment stops.¹²

The biofilm also functions as a cooperative structure. Other BV-associated bacteria like Prevotella bivia and Fannyhessea vaginae (formerly Atopobium vaginae) can incorporate into a pre-existing Gardnerella biofilm, and once there, they influence gene expression in ways that may help maintain the biofilm’s stability.¹³ Gardnerella even appears to help keep its partner species alive: in lab conditions, Atopobium vaginae lost about 92% of its viability within 48 hours when grown alone, but maintained its cell numbers when grown alongside Gardnerella, apparently because of some extracellular molecules Gardnerella releases.¹⁴ When all three organisms grow together in a biofilm, they significantly alter each other’s gene expression in ways that may amplify the community’s disease-causing potential.¹⁵

This is why a positive Gardnerella DNA test after treatment doesn’t necessarily mean treatment failed. The organism is extremely difficult to eliminate entirely. The clinical question is not “is it gone?” but “has the community been pushed back enough for Lactobacillus to re-establish dominance?”

Pregnancy and Gardnerella Loads

Pregnant women sometimes encounter Gardnerella DNA results on prenatal screening panels or during workups for vaginal symptoms. Gardnerella species have been identified as risk factors for preterm birth,¹⁶ and at least one study found that high levels of Gardnerella vaginalis measured two to four weeks before spontaneous preterm birth were predictive of that outcome, with over a tenfold increased risk when comparing the highest to lowest third of bacterial levels.¹⁷

That sounds alarming, but the clinical picture is complicated. The U.S. Preventive Services Task Force has recommended against routine screening and treatment of asymptomatic BV in pregnant women, reflecting uncertainty about whether treating asymptomatic cases actually improves pregnancy outcomes.¹⁸ A positive Gardnerella DNA result during pregnancy warrants a conversation with your provider, particularly if the load is high or you have symptoms, but it is not a reason to panic.

Can You Transmit Gardnerella to a Partner?

BV has traditionally been classified as not sexually transmitted, but recent research has muddied that distinction. Metagenomic sequencing of sexual networks has documented cases consistent with heterosexual transmission of Gardnerella species (specifically Gardnerella leopoldii, one of the newly named species) between partners.¹⁹ Studies of men have found that urethral Gardnerella and Gardnerella-specific immune responses were present only in men who reported prior penile-vaginal sex, not in sexually inexperienced men.²⁰

This does not mean that BV behaves like a classic sexually transmitted infection where treating one partner cures both. BV is a community-level shift in the vaginal ecosystem, not a single-organism infection. Gardnerella can be shared between partners, and Mycoplasma hominis, another BV-associated organism, shows a significant positive correlation with Gardnerella loads when both are present, suggesting the two often travel together.²¹ But whether treating male partners reduces BV recurrence in women remains an open question. The evidence is thin enough that most guidelines don’t currently recommend routine partner treatment.

Gardnerella, Pelvic Inflammatory Disease, and Broader Reproductive Health

Women sometimes worry that a positive Gardnerella result puts them at risk for pelvic inflammatory disease (PID). The relationship is not straightforward. One study found that BV and high Gardnerella levels alone did not significantly increase PID risk in the overall population, though women with two or more recent sexual partners who also had BV-associated bacteria did face higher PID rates.²² A separate analysis found that a combination of BV-related organisms at high levels roughly doubled the risk of PID.²³ Cervical samples from women with PID often show both Lactobacillus and Gardnerella dominating the cervical microbiota, while the upper pelvic microbiota is dominated by different organisms entirely.²⁴

The takeaway: Gardnerella by itself is not a strong predictor of PID, but BV as a broader microbial pattern, with high loads of multiple anaerobic organisms and depleted Lactobacillus, can raise risk, particularly when combined with sexual behavior factors. A single positive Gardnerella DNA result is very far from a PID diagnosis.

Gardnerella Beyond the Vaginal Tract

Though Gardnerella vaginalis is overwhelmingly associated with the vaginal microbiome, rare cases of extra-genital infections have been documented. In women, these typically occur after gynecologic surgery or in the context of pregnancy complications, and they tend to be polymicrobial rather than caused by Gardnerella alone.²⁵ There are even case reports of Gardnerella bloodstream infections in men, including one striking case involving endocarditis and septic emboli in the brain and kidneys.²⁶ These are extremely rare scenarios and should not cause alarm over a routine vaginal DNA test, but they illustrate that the organism is not exclusively a women’s-health concern.

What to Do with Your Results

If you have a positive Gardnerella vaginalis DNA result and symptoms of BV, such as a thin grayish-white discharge with a strong fishy odor, the result supports a BV diagnosis and your provider will likely discuss antibiotic treatment. Standard therapy is metronidazole or clindamycin, either oral or vaginal. Be aware that recurrence is common because of the biofilm issue discussed earlier.

If you have a positive result but no symptoms, the situation is more nuanced. Current evidence does not strongly support treating asymptomatic Gardnerella colonization in non-pregnant women.¹⁸ This is an area of active research, and some providers will consider the full clinical picture, including pregnancy status, plans for gynecologic procedures, and concurrent STI testing, before deciding. In many cases, a positive Gardnerella DNA result in an asymptomatic person is simply a reflection of normal vaginal ecology and requires nothing beyond a conversation with your clinician.

Emerging Alternatives to Antibiotics

Because standard antibiotic treatment leaves biofilms largely intact, researchers have been exploring other approaches. These include probiotics designed to reintroduce protective Lactobacillus, vaginal acidifying agents that lower pH to favor Lactobacillus growth, antiseptics, plant-derived compounds, vaginal microbiome transplantation from healthy donors, and bacteriophage-derived enzymes (endolysins) engineered to break apart biofilms.²⁷ Most of these remain in early stages, but they reflect a growing recognition that BV is an ecological problem that probably requires ecological solutions rather than just killing bacteria.

The Emotional Side of a Positive Result

Getting a lab result that flags a bacterium you’ve never heard of can trigger real anxiety, especially when the word “vaginalis” makes it sound like something is wrong with you specifically. Research on how BV affects women psychologically has found that the most distressing symptom is odor, which makes women feel “dirty,” “unattractive,” and “ashamed,” and often leads to avoidance of sexual activity even when partners are supportive.²⁸ Some of that shame is tied to broader stigma around vaginal health and the assumption that anything detected must be a sexually transmitted infection.

A positive Gardnerella DNA result, particularly one that arrives via a mail-in STI panel or a wellness screen, can trigger similar feelings even when the result is clinically meaningless. Knowing that the bacterium is a normal inhabitant of most women’s bodies may not fully erase the anxiety, but it should help reframe the result as routine rather than alarming. If BV is confirmed and recurrence becomes a pattern, the emotional burden is real and worth discussing with your provider alongside the medical options.